HCP
BBIO icon

Hexagon Capital Partners’s BridgeBio Pharma BBIO Stock Holding History

Hexagon Capital Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2
Closed -$53 – 1427
2023
Q3 		$53 Buy
+2
New +$57 ﹤0.01% 1388

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hexagon Capital Partners's BBIO Position: Q4 2023 in Review

Hexagon Capital Partners sold out of BridgeBio Pharma (BBIO) in Q4 2023, closing a stake of 2 shares — an estimated $53 sold.

Hexagon Capital Partners first reported a position in BBIO in Q3 2023 and held it in 1 quarter. The position peaked at $53 in Q3 2023. 247 funds tracked by Wall St. Rank hold BBIO as of Q4 2023.

  • Hexagon Capital Partners reported no remaining BridgeBio Pharma position as of Q4 2023 after selling out during the quarter.
  • Hexagon Capital Partners sold 2 BridgeBio Pharma shares in Q4 2023, an estimated $53.
  • Hexagon Capital Partners first reported a position in BridgeBio Pharma in Q3 2023 and held it in 1 quarter.
  • Hexagon Capital Partners's BridgeBio Pharma position peaked at $53 in Q3 2023.
  • 247 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2023.

Based on Hexagon Capital Partners's 13F filing for Q4 2023, filed 5 Feb 2024.